Results 51 to 60 of about 39,275 (210)

GLP-1 Receptor Agonists and Kidney Protection

Medicina, 2019
Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomerular filtration rate (GFR).
Eulalia Greco, Giuseppina Russo, Annalisa Giandalia, Francesca Viazzi, Roberto Pontremoli, Salvatore De Cosmo   +5 more
openaire   +3 more sources

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

Scientific Reports, 2019
Enteroendocrine L-cell derived peptide hormones, notably glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), have become important targets in the treatment of type 2 diabetes, obesity and intestinal diseases.
Mette Simone Aae Madsen, Jacob Bak Holm, Albert Pallejà, Pernille Wismann, Katrine Fabricius, Kristoffer Rigbolt, Martin Mikkelsen, Morten Sommer, Jacob Jelsing, Henrik Bjørn Nielsen, Niels Vrang, Henrik H. Hansen   +11 more
doaj   +1 more source

Socioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study

Obesity Facts
Introduction: In Sweden, glucagon-like peptide-1 (GLP-1) receptor agonists are subsidized for diabetes indication but not for obesity. Unregulated off-label prescription of GLP-1 receptor agonists for obesity treatment may raise concerns about
Laura Pazzagli, Ylva Trolle Lagerros
doaj   +1 more source

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]

, 2016
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo, Bonora, Enzo, Fadini, GIAN PAOLO, Prato, Stefano Del, Sesti, Giorgio   +4 more
core   +3 more sources

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists

Molecular Metabolism, 2021
Objective: We assessed the spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics of GIPR mono-agonists, GLP-1R mono-agonists including semaglutide, and GLP-1/GIP dual-agonists MAR709 and tirzepatide.
Aaron Novikoff, Shannon L. O'Brien, Miriam Bernecker, Gerald Grandl, Maximilian Kleinert, Patrick J. Knerr, Kerstin Stemmer, Martin Klingenspor, Anja Zeigerer, Richard DiMarchi, Matthias H. Tschöp, Brian Finan, Davide Calebiro, Timo D. Müller   +13 more
doaj   +1 more source

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly [PDF]

, 2016
PURPOSE: Cushing’s disease (CD) and acromegaly are characterized by excessive hormone secretion resulting in comorbidities such as impaired glucose metabolism, diabetes and hypertension.
Silverstein, Julie M
core   +2 more sources

Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor. [PDF]

PLoS ONE, 2012
Glucagon-like peptide-1 (GLP-1) released from intestinal L cells in response to nutrients has many physiological effects but particularly enhances glucose-dependent insulin release through the GLP-1 receptor (GLP-1R).
Naichang Li, Jing Lu, Gary B Willars
doaj   +1 more source

Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer

Frontiers in Pharmacology
Background: Glucagon-like peptide-1 (GLP-1) has crucial impact on glycemic control and weight loss physiologically. GLP-1 receptor agonists have been approved for treatment of diabetes and obesity.
Chaojun Zhu, Yihong Lai, Chengdong Liu, Lan Teng, Yuxin Zhu, Xinyu Lin, Xinyi Fu, Qiuhua Lai, Side Liu, Side Liu, Xiaohan Zhou, Yuxin Fang   +11 more
doaj   +1 more source

Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment

Diabetes & Vascular Disease Research, 2020
Introduction: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and ...
Takeyuki Hiramatsu, Hiroki Ito, Shota Okumura, Yuko Asano, Daiki Iguchi, Shinji Furuta   +5 more
doaj   +1 more source

Inhibition of Y1 receptor signaling improves islet transplant outcome [PDF]

, 2017
Failure to secrete sufficient quantities of insulin is a pathological feature of type-1 and type-2 diabetes, and also reduces the success of islet cell transplantation.
A Ali-Rachedi, A Thonpho, AD Nguyen, AG Nieuwenhuizen, AM Shapiro, AM Shapiro, American Diabetes, A., AR Saltiel, C Ammala, C Postic, C Ricordi, C Ricordi, CR Gustavsen, D Boey, D Boey, D Ize-Ludlow, DL Eizirik, DM Sousa, E Karra, G Bertrand, H Matsuda, H Yajima, HA Wieland, J Cantley, JM Sosenko, JY Kim, K Loh, K Yang, L Zhang, L Zhang, LA Selbie, M Jackerott, N Butta, O Idevall-Hagren, RA Stokes, RL Batterham, RP Robertson, S Kassis, S Seino, S Walters, T Yada, TL Belle van, TT Ngo, W Shao, Y Kashima, YC Shi, YC Shi   +46 more
core   +5 more sources